Breaking News Instant updates and real-time market news.

MRNS

Marinus Pharmaceuticals

$4.09

-0.23 (-5.32%)

, SAGE

Sage Therapeutics

$166.38

-5.84 (-3.39%)

05:56
03/20/18
03/20
05:56
03/20/18
05:56

Mizuho sees Marinus following in footsteps of Sage, starts with Buy rating

Mizuho analyst Difei Yang last night initiated Marinus Pharmaceuticals with a Buy rating and $13 price target. The company, following in the footsteps of Sage Therapeutics (SAGE), is developing a similar molecule in Ganaxolone with potential in multiple central nervous system indications including postpartum depression, Yang tells investors in a research note. The analyst sees the recent positive data from Sage in postpartum depression and major depressive disorder as positive read-throughs for Marinus.

MRNS

Marinus Pharmaceuticals

$4.09

-0.23 (-5.32%)

SAGE

Sage Therapeutics

$166.38

-5.84 (-3.39%)

  • 30

    May

MRNS Marinus Pharmaceuticals
$4.09

-0.23 (-5.32%)

09/12/17
JMPS
09/12/17
NO CHANGE
Target $11
JMPS
Outperform
Marinus price target raised to $11 from $5 at JMP Securities
JMP Securities analyst Jason Butler raised his price target on Marinus Pharmaceuticals to $11 from $5 after the company reported Phase 2 clinical trial results in patients with CDKL5 disorder that he said support the potential for the drug to have "meaningful clinical benefit." The analyst, who added that the safety profile of ganaxolone "looks clean," keeps an Outperform rating on Marinus shares.
03/19/18
MZHO
03/19/18
INITIATION
Target $13
MZHO
Buy
Marinus Pharmaceuticals initiated with a Buy at Mizuho
Mizuho initiated Marinus Pharmaceuticals with a Buy and $13 price target.
SAGE Sage Therapeutics
$166.38

-5.84 (-3.39%)

01/31/18
BMOC
01/31/18
NO CHANGE
Target $203
BMOC
Outperform
Sage data support exploring sleep disorders, says BMO Capital
In a relatively small proof-of-concept study, SAGE-217 demonstrated a potential benefit in improving sleep, BMO Capital analyst Gary Nachman tells investors in a research note. These data support Sage Therapeutics exploring SAGE-217 for sleep disorders, the analyst adds. He believes validation for sleep disorders opens up the product to a "whole other large therapeutic area that could drive further upside." Nachman reiterates an Outperform rating on Sage with a $203 price target. The stock in morning trading is up 2.5% to $189.21.
02/26/18
MSCO
02/26/18
INITIATION
Target $225
MSCO
Overweight
Sage Therapeutics initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Matthew Harrison started Sage Therapeutics with an Overweight rating and $225 price target, stating that he sees brexanolone for post-partum depression providing a "solid base" that can generate $775M in peak U.S. sales. The real long-term value he sees, though, is from next-gen agent SAGE-217, which Harrison said has initial "robust" data in depression and expansion opportunities into bipolar disorder and insomnia.
02/26/18
02/26/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Walmart (WMT) initiated with a Neutral and Target (TGT) initiated with an Outperform at Credit Suisse. 2. Hudson (HUD) initiated with a Buy at Goldman Sachs, a Buy at UBS, an Equal Weight at Morgan Stanley and an Outperform at Credit Suisse. 3. VICI Properties (VICI) initiated with a Buy at Stifel, a Neutral at Goldman Sachs and an Equal Weight at Barclays. 4. Sage Therapeutics (SAGE) initiated with an Overweight at Morgan Stanley. 5. Sol-Gel Technologies (SLGL) initiated with a Buy at Jefferies and an Outperform at BMO Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/28/18
RHCO
02/28/18
NO CHANGE
Target $203
RHCO
Buy
Sage Therapeutics price target raised to $203 from $178 at SunTrust
SunTrust analyst Edward Nash raised his price target on Sage Therapeutics to $203, updating his model on the outline for Brexanolone's NDA filing for postpartum depression remaining on track for the first half of this year leading to a potential commercial launch. Nash keeps his Buy rating on Sage Therapeutics, adding that 2018 may be another catalyst-rich year with multiple trial initiations and readouts expected - including top-line data from the expanded Phase II study of SAGE-217 in PPD.

TODAY'S FREE FLY STORIES

SPY

SPDR S&P 500 ETF Trust

$255.30

0.18 (0.07%)

, SPX

S&P 500

$0.00

(0.00%)

14:57
12/18/18
12/18
14:57
12/18/18
14:57
Periodicals
Democrats reject GOP offer to avert shutdown, Washington Post says »

Congressional Republicans…

SPY

SPDR S&P 500 ETF Trust

$255.30

0.18 (0.07%)

SPX

S&P 500

$0.00

(0.00%)

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAT

Mattel

$10.93

-0.25 (-2.24%)

14:55
12/18/18
12/18
14:55
12/18/18
14:55
Options
Mattel put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

14:55
12/18/18
12/18
14:55
12/18/18
14:55
General news
Treasury Action: Treasuries are vulnerable to a knee jerk selloff Wednesday »

Treasury Action:…

MU

Micron

$34.82

0.93 (2.74%)

14:49
12/18/18
12/18
14:49
12/18/18
14:49
Options
Micron options imply 12.3% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 08

    Jan

MLM

Martin Marietta

$177.29

1.74 (0.99%)

14:46
12/18/18
12/18
14:46
12/18/18
14:46
Hot Stocks
Martin Marietta takes action after 'say on pay' vote, reviewing executive pay »

In connection with Martin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$103.68

0.7 (0.68%)

, AMD

AMD

$19.57

0.74 (3.93%)

14:36
12/18/18
12/18
14:36
12/18/18
14:36
Periodicals
Microsoft next Xbox console is codenamed Anaconda, Verge reports »

Microsoft's (MSFT)…

MSFT

Microsoft

$103.68

0.7 (0.68%)

AMD

AMD

$19.57

0.74 (3.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

  • 03

    Mar

  • 04

    Mar

BIIB

Biogen

$293.41

-19.81 (-6.32%)

, RHHBY

Roche

$0.00

(0.00%)

14:32
12/18/18
12/18
14:32
12/18/18
14:32
Recommendations
Biogen drops after Bernstein sees potential downside of $100 on Q1 risks »

Bernstein analyst Aaron…

BIIB

Biogen

$293.41

-19.81 (-6.32%)

RHHBY

Roche

$0.00

(0.00%)

MYL

Mylan

$29.00

0.15 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 24

    Dec

  • 18

    Mar

DUK

Duke Energy

$87.77

-0.31 (-0.35%)

14:32
12/18/18
12/18
14:32
12/18/18
14:32
Hot Stocks
Former Duke Energy chairman and CEO Jim Rogers dies »

Jim Rogers, the former…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CFMS

Conformis

$0.45

-0.0215 (-4.54%)

14:31
12/18/18
12/18
14:31
12/18/18
14:31
Hot Stocks
Conformis enters common stock purchase agreement with Lincoln Park Capital Fund »

Conformis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDC

First Data

$16.60

0.18 (1.10%)

14:30
12/18/18
12/18
14:30
12/18/18
14:30
Options
Hefty call spreads in First Data for the second time in three trading days »

Hefty call spreads in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

BIIB

Biogen

$293.35

-19.87 (-6.34%)

, MYL

Mylan

$29.02

0.17 (0.59%)

14:29
12/18/18
12/18
14:29
12/18/18
14:29
Recommendations
Biogen, Mylan analyst commentary  »

Piper says Biogen…

BIIB

Biogen

$293.35

-19.87 (-6.34%)

MYL

Mylan

$29.02

0.17 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APEN

Apollo Endosurgery

$3.57

0.08 (2.29%)

14:27
12/18/18
12/18
14:27
12/18/18
14:27
Recommendations
Apollo Endosurgery analyst commentary  »

Craig-Hallum says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:20
12/18/18
12/18
14:20
12/18/18
14:20
General news
Canada CPI preview »

Canada CPI preview:…

TCEHY

Tencent

$0.00

(0.00%)

, DIS

Disney

$109.75

-0.88 (-0.80%)

14:18
12/18/18
12/18
14:18
12/18/18
14:18
Periodicals
'PUBG' on mobile has as many total users as 'Fortnite,' Verge reports »

The mobile version of…

TCEHY

Tencent

$0.00

(0.00%)

DIS

Disney

$109.75

-0.88 (-0.80%)

KKR

KKR

$19.89

0.09 (0.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

  • 11

    Feb

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
12/18/18
12/18
14:17
12/18/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
12/18/18
12/18
14:16
12/18/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDR

McDermott

$6.72

-0.39 (-5.49%)

14:05
12/18/18
12/18
14:05
12/18/18
14:05
Options
McDermott call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GD

General Dynamics

$163.24

-0.19 (-0.12%)

14:02
12/18/18
12/18
14:02
12/18/18
14:02
Hot Stocks
General Dynamics unit awarded Department of Education contract »

General Dynamics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

APHA

Aphria

$5.87

0.43 (7.90%)

, TLRY

Tilray

$76.52

10.63 (16.13%)

14:00
12/18/18
12/18
14:00
12/18/18
14:00
Hot Stocks
Citron touts cannabis name Aphria again, sees shares above $8 by year-end »

Shares of Aphria (APHA)…

APHA

Aphria

$5.87

0.43 (7.90%)

TLRY

Tilray

$76.52

10.63 (16.13%)

ACB

Aurora Cannabis

$5.57

0.03 (0.54%)

MO

Altria Group

$51.40

-0.97 (-1.85%)

NVS

Novartis

$85.56

-0.24 (-0.28%)

CRON

Cronos Group

$11.50

0.375 (3.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jan

  • 07

    Feb

STZ

Constellation Brands

$172.45

-3.61 (-2.05%)

13:55
12/18/18
12/18
13:55
12/18/18
13:55
Options
Constellation Brands put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

MU

Micron

$34.81

0.92 (2.71%)

, UMC

UMC

$1.81

-0.005 (-0.28%)

13:50
12/18/18
12/18
13:50
12/18/18
13:50
On The Fly
Fly Intel: What to watch for in Micron's earnings report »

Micron (MU) is scheduled…

MU

Micron

$34.81

0.92 (2.71%)

UMC

UMC

$1.81

-0.005 (-0.28%)

INTC

Intel

$48.04

0.95 (2.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 04

    Jan

  • 07

    Jan

  • 08

    Jan

VOD

Vodafone

$19.88

-0.13 (-0.65%)

13:48
12/18/18
12/18
13:48
12/18/18
13:48
Periodicals
Vodafone preparing to remove PwC as auditor, Sky News reports »

Vodafone is preparing to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOGL

Alphabet Class A

$1,057.23

30.69 (2.99%)

, GOOG

Alphabet

$1,046.01

28.41 (2.79%)

13:40
12/18/18
12/18
13:40
12/18/18
13:40
Periodicals
Search engine startup claims Google still blocking competition, TechCrunch says »

The European Commission…

GOOGL

Alphabet Class A

$1,057.23

30.69 (2.99%)

GOOG

Alphabet

$1,046.01

28.41 (2.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

KMX

CarMax

$60.38

0.11 (0.18%)

13:40
12/18/18
12/18
13:40
12/18/18
13:40
Options
7X average daily option volume in CarMax driven by an earnings hedge »

7X average daily option…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Dec

  • 31

    Jan

  • 01

    Feb

BIDU

Baidu

$169.94

0.03 (0.02%)

13:35
12/18/18
12/18
13:35
12/18/18
13:35
Hot Stocks
Unity Technologies, Baidu partner to develop autonomous vehicle simulation »

Unity Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.